NYSE:ARA American Renal Associates (ARA) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$11.33▼$11.5250-Day Range$11.46▼$11.5252-Week Range$5.57▼$11.98Volume9,831 shsAverage Volume106,940 shsMarket Capitalization$397.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get American Renal Associates alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About American Renal Associates Stock (NYSE:ARA)American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. ARA Stock News HeadlinesAugust 31, 2023 | benzinga.comBayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of CardiologyFebruary 22, 2023 | finance.yahoo.comAnemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.January 11, 2023 | finance.yahoo.comLiberation From Renal Replacement Therapy and Early Initiation to Be Supported by The Kidney Function Biomarker Proenkephalin A 119-159 (penKid)January 2, 2023 | finance.yahoo.comContinuous Renal Replacement Therapy Global Market Report 2022: Rising Prevalence of Acute Kidney Injuries Drives DemandOctober 7, 2022 | bbc.comDalian Atkinson: Footballer killed hours before renal treatmentJune 22, 2022 | finance.yahoo.comARA Appoints James Myers Vice President, Program Innovation and GrowthJune 20, 2022 | thestreet.comAmerican Renal Associates Holdings, Inc. NewsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.December 6, 2021 | markets.businessinsider.comSEC Charges Dialysis Provider and Three Former Senior Executives with Revenue Manipulation SchemeDecember 6, 2021 | law360.comSEC Hits Dialysis Co., Execs With Accounting Fraud ClaimDecember 6, 2021 | nasdaq.comU.S. SEC charges dialysis provider, three former executives with revenue manipulationOctober 21, 2021 | sg.finance.yahoo.comStrive Health Unveils Strive Care Partners, Reaches 500 Nephrology PartnersOctober 19, 2021 | investing.comAmerican Renal Associates Holdings Inc (ARA)See More Headlines Receive ARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolNYSE:ARA CUSIPN/A CIK1498068 Webwww.americanrenal.com Phone978-922-3080FaxN/AEmployees4,977Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.26 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,790,000.00 Net Margins-2.04% Pretax MarginN/A Return on Equity-3.56% Return on Assets-0.24% Debt Debt-to-Equity Ratio7.54 Current Ratio1.05 Quick Ratio1.02 Sales & Book Value Annual Sales$822.52 million Price / Sales0.48 Cash Flow$1.69 per share Price / Cash Flow6.80 Book Value$2.59 per share Price / Book4.45Miscellaneous Outstanding Shares34,543,000Free FloatN/AMarket Cap$397.94 million OptionableOptionable Beta1.11 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Joseph A. Carlucci (Age 66)Co-Founder, CEO & Chairman Comp: $1.06MMr. Syed T. Kamal (Age 67)Co-Founder, Pres & Director Comp: $947.14kDr. Don E. Williamson (Age 58)Exec. VP & COO Comp: $1.22MMr. Mark C. Herbers (Age 65)Interim CFO & Interim Chief Accounting Officer Mr. Richard Pacheco CFEAVA, MBA, VP of Admin.Mr. Neal MinahanChief Compliance Officer & VPMs. Victoria A. Labriola Esq.M.B.A., VP, Gen. Counsel & Sec.Ms. Jennifer HoodVP of HRDr. Richard Cronin M.D.Chief Medical OfficerMs. Shari Cousins R.N.C.N.N., Sr. VP of Clinical & Regulatory ServicesMore ExecutivesKey CompetitorsSchrödingerNASDAQ:SDGRTeladoc HealthNYSE:TDOCSoleno TherapeuticsNASDAQ:SLNOWarby ParkerNYSE:WRBYAvadel PharmaceuticalsNASDAQ:AVDLView All Competitors ARA Stock Analysis - Frequently Asked Questions How were American Renal Associates' earnings last quarter? American Renal Associates Holdings, Inc. (NYSE:ARA) announced its earnings results on Wednesday, November, 11th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.09. The firm earned $209.69 million during the quarter, compared to analyst estimates of $211.50 million. American Renal Associates had a negative trailing twelve-month return on equity of 3.56% and a negative net margin of 2.04%. What is Joseph Carlucci's approval rating as American Renal Associates' CEO? 62 employees have rated American Renal Associates Chief Executive Officer Joseph Carlucci on Glassdoor.com. Joseph Carlucci has an approval rating of 57% among the company's employees. This puts Joseph Carlucci in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. When did American Renal Associates IPO? American Renal Associates (ARA) raised $161 million in an initial public offering on Thursday, April 21st 2016. The company issued 7,500,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers. What other stocks do shareholders of American Renal Associates own? Based on aggregate information from My MarketBeat watchlists, some other companies that American Renal Associates investors own include Zevra Therapeutics (KMPH), Exelixis (EXEL), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Spectrum Pharmaceuticals (SPPI) and Akorn (AKRX). This page (NYSE:ARA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding American Renal Associates Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share American Renal Associates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.